GlobeNewswire

Novavax Reports First Quarter 2019 Financial Results

Share

            Company to Host Conference Call Today at 4:30 p.m. ET

GAITHERSBURG, Md., May 02, 2019 (GLOBE NEWSWIRE) -- Novavax, Inc., (Nasdaq: NVAX) today announced its financial results and operational highlights for the first quarter ended March 31, 2019.

First Quarter 2019 and Subsequent Operational Highlights

ResVax ™ Program

  • In February 2019, Novavax announced top-line data from the Prepare™ trial, which was designed to determine the efficacy of ResVax™ against medically significant respiratory syncytial virus (RSV)-positive lower respiratory tract infection (LRTI) in infants. ResVax is the first RSV vaccine to demonstrate efficacy in infants.
     
  • In April 2019, Novavax presented additional results at the World Vaccine Congress in Washington, D.C. from the Prepare trial of ResVax. Although the Prepare trial results did not meet the pre-specified primary efficacy endpoint, it demonstrated efficacy against RSV LRTI hospitalizations, a pre-specified secondary endpoint. RSV LRTI hospitalization is not only an important indication of the severity of RSV disease in infants, it also reflects a significant economic burden to global health systems.

NanoFlu™ Program

  • In January 2019, Novavax announced positive top-line results of its Phase 2 clinical trial of NanoFlu comparing various quadrivalent formulations, with or without Novavax’ Matrix-M™ adjuvant, with two U.S.-licensed influenza vaccines in older adults. These results show that NanoFlu with Matrix-M generated enhanced immune responses compared to the unadjuvanted formulation, and importantly, showed superior hemagglutination inhibition antibody (HAI) responses against wild-type A(H3N2) viruses, including drifted strains, when compared to Fluzone® High-Dose, the leading flu vaccine in older adults.

Key Upcoming Events

  • Meet with the FDA, European regulatory agencies, and potentially other national regulatory agencies during the second and third quarters, to assess opportunities for submission of marketing applications for ResVax.
  • Reach agreement with the FDA during the third quarter of 2019 on a proposed Phase 3 clinical trial design for NanoFlu utilizing accelerated approval criteria for licensure.
  • Present ResVax Phase 3 clinical trial data at the 37th Annual Meeting of the European Society for Paediatric Infectious Diseases (ESPID) on May 7, 2019.

Financial Results for the First Quarter Ended March 31, 2019

Novavax reported a net loss of $43.2 million, or $0.11 per share, for the first quarter of 2019, compared to a net loss of $46.4 million, or $0.14 per share, for the first quarter of 2018.

Novavax revenue in the first quarter of 2019 was $4.0 million, compared to $9.7 million in the same period in 2018. This 59% decrease was driven by the completion of enrollment of the Prepare trial in the second quarter of 2018.

Research and development expenses decreased 20% to $35.5 million in the first quarter of 2019, compared to $44.5 million for the same period in 2018. This decrease was primarily due to decreased development activities, including lower clinical trial costs, of ResVax.

General and administrative expenses were flat at $8.7 million in the first quarter of 2019, compared to the same period of 2018.

Interest income (expense), net was ($3.0) million in the first quarter of 2019, compared to ($2.9) million for the same period of 2018.

As of March 31, 2019, Novavax had $108.7 million in cash, cash equivalents, marketable securities and restricted cash, compared to $103.9 million as of December 31, 2018. Net cash used in operating activities for the first quarter of 2019 was $50.6 million, compared to $66.1 million for same period in 2018.

Conference Call

Novavax will host its quarterly conference call today at 4:30 p.m. ET. The dial-in numbers for the conference call are (877) 212-6076 (Domestic) or (707) 287-9331 (International), passcode 5394082. A replay of the conference call will be available starting at 7:30 p.m. ET on May 2, 2019 until 7:30 p.m. ET on May 9, 2019. To access the replay by telephone, dial (855) 859-2056 (Domestic) or (404) 537-3406 (International) and use passcode 5394082.

A webcast of the conference call can also be accessed via a link on the home page of the Novavax website (novavax.com) or through the “Investor Info”/“Events” tab on the Novavax website. A replay of the webcast will be available on the Novavax website until August 2, 2019.

About RSV in Infants

Globally, RSV (respiratory syncytial virus) is the leading viral cause of severe lower respiratory tract disease in infants and young children. It is the second leading cause of death in children under one year of age. Estimated annual hospitalizations of 1.4 million and an estimated 27,300 in-hospital deaths were due to RSV acute lower respiratory infection in children under six months of age. RSV results in a total global economic burden of $6.2 billion annually.

In the U.S., RSV is the leading cause of hospitalization of infants. Estimated annual hospitalizations are up to 76,000. While RSV can impact all infants, babies under six months of age are among those at highest risk, as approximately 77% of all first-year RSV infections occur before six months. In the U.S., the total economic burden is $2.7 billion annually.

About ResVax™

ResVax is an RSV fusion (F) protein recombinant nanoparticle vaccine with aluminum phosphate as an adjuvant. It is being developed to protect infants from RSV disease via maternal immunization, which may offer the best method of protection from RSV disease in infants through the first months of life. In February 2019, Novavax announced top-line data from Prepare™, a global Phase 3 clinical trial in 4,636 pregnant women, at least 3,000 of whom have received the vaccine, and their infants. Prepare is supported by an $89.1 million grant from the Bill & Melinda Gates Foundation (BMGF).

About Influenza

Influenza is a world-wide infectious disease that causes illness in humans with symptoms ranging from mild to life-threatening or even death. Serious illness occurs not only in susceptible populations such as infants, young children and older adults, but also in the general population largely because of infection by continuously evolving strains of influenza which can evade the existing protective antibodies in humans. An estimated one million deaths globally each year are attributed to influenza. Current estimates for seasonal influenza vaccine growth in the top seven markets (U.S., Japan, France, Germany, Italy, Spain and UK), show a potential increase from approximately $3.2 billion in 2012-13 season to $5.3 billion by the 2021-22 season.

About NanoFlu™ and Matrix M™

NanoFlu is a recombinant hemagglutinin (HA) protein nanoparticle influenza vaccine produced by Novavax in its SF9 insect cell baculovirus system. NanoFlu uses HA protein amino acid sequences that are the same as the recommended wild-type circulating virus HA sequences. NanoFlu contains Novavax’ patented saponin-based Matrix-M adjuvant, which is potent and well- stimulates both high quality and durable antibody responses as well as multifunctional CD4 and CD8 T-cell responses. In January 2019, Novavax announced positive top-line data from its Phase 2 clinical trial in older adults of quadrivalent formulations of NanoFlu in 1,375 healthy older adults across clinical sites in the U.S.

About Accelerated Approval

Accelerated approval may be granted for certain biological products that have been studied for their safety and effectiveness in treating serious or life-threatening illnesses and that provide meaningful therapeutic benefit over existing treatments. Such an approval will be based on adequate and well-controlled clinical trials establishing that the biological product has an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit. For seasonal influenza vaccines, the hemagglutination inhibition (HAI) antibody response may be an acceptable surrogate marker of activity that is reasonably likely to predict clinical benefit. To be considered for accelerated approval, a biologics license application for a new seasonal influenza vaccine should include results from one or more well-controlled studies designed to meet immunogenicity endpoints and a commitment to conduct confirmatory post-marketing studies of clinical effectiveness in preventing influenza.

About Novavax

Novavax, Inc. (Nasdaq:NVAX) is a late-stage biotechnology company that drives improved health globally through the discovery, development, and commercialization of innovative vaccines to prevent serious infectious diseases. Its two priority programs are ResVax™, its RSV vaccine for infants via maternal immunization, and NanoFlu™, its quadrivalent influenza nanoparticle vaccine. Novavax’ proprietary recombinant technology platform combines the power and speed of genetic engineering to efficiently produce a new class of highly immunogenic nanoparticles addressing urgent global health needs.

For more information, visit www.novavax.com and connect with us on Twitter and LinkedIn.

Forward-Looking Statements

Statements herein relating to the future of Novavax and the ongoing development of its vaccine and adjuvant products are forward-looking statements. Novavax cautions that these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include those identified under the heading “Risk Factors” in the Novavax Annual Report on Form 10-K for the year ended December 31, 2018, and Quarterly Report on Form 10-Q for the period ended March 31, 2019, as filed with the Securities and Exchange Commission (SEC). We caution investors not to place considerable reliance on the forward-looking statements contained in this press release. You are encouraged to read our filings with the SEC, available at sec.gov, for a discussion of these and other risks and uncertainties. The forward-looking statements in this press release speak only as of the date of this document, and we undertake no obligation to update or revise any of the statements. Our business is subject to substantial risks and uncertainties, including those referenced above. Investors, potential investors, and others should give careful consideration to these risks and uncertainties.


NOVAVAX, INC.  
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS  
(in thousands, except per share information)

(unaudited)
 
                     
          Three Months Ended
          March 31
                2019       2018  
               
               
Revenue         $      3,982     $      9,653  
                   
Expenses:              
  Research and development           35,473       44,514  
  General and administrative           8,732       8,652  
    Total expenses           44,205       53,166  
Loss from operations           (40,223 )     (43,513 )
Interest income (expense), net           (2,983 )     (2,872 )
Other income (expense)           (12 )     33  
Net loss         $     (43,218 )   $     (46,352 )
                   
Basic and diluted net loss per share         $     (0.11 )   $     (0.14 )
Basic and diluted weighted average              
  number of common shares outstanding           408,843       336,972  

SELECTED CONSOLIDATED BALANCE SHEET DATA
(in thousands)

  March 31,
2019
  December 31,
2018
  (unaudited)    
       
Cash and cash equivalents 97,711     70,154  
Marketable securities 2,484     21,980  
Total restricted cash 8,488     11,805  
Total current assets 123,394     119,276  
Working capital 91,898     73,737  
Total assets 221,319     207,978  
Notes payable 319,543     319,187  
Total stockholders’ deficit (150,583 )   (167,935 )

Contacts:      

Investors
Novavax, Inc.
Erika Trahan
ir@novavax.com
240-268-2000

Westwicke
John Woolford
john.woolford@westwicke.com
443-213-0506

 

About GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

INDKALDELSE til ordinær generalforsamling i FLSmidth & Co. A/S2.6.2020 14:46:17 CESTpressemeddelelse

Company Announcement No. 10-2020 Bestyrelsen indkalder herved til ordinær generalforsamling fredag den 26. juni 2020 kl. 16.00 på selskabets adresse, Vigerslev Allé 77, 2500 Valby. Af hensyn til alles sikkerhed og for at mindske risikoen for smittespredning af COVID-19 henstiller vi til, at vores aktionærer ikke møder op fysisk på generalforsamlingen, men brevstemmer eller giver fuldmagt og følger generalforsamlingen via livestreaming på hjemmesiden. Ledelsen vil også være meget begrænset repræsenteret for at mindske smitterisikoen. Dagsorden: Bestyrelsens beretning om selskabets virksomhed i 2019Forelæggelse og godkendelse af årsrapport for 2019Godkendelse af honorarer til bestyrelsen: a. Endelig godkendelse af honorarer for 2019 Bestyrelsen foreslår uændret godkendelse af honorarerne for 2019, som blev forhåndsgodkendt af generalforsamlingen i 2019. Honorarerne er baseret på et grundhonorar på DKK 450.000 (”Grundhonoraret”) med dobbelt honorar til næstformanden og tredobbelt honorar

NOTICE TO CONVENE the Annual General Meeting of FLSmidth & Co. A/S2.6.2020 14:46:17 CESTPress release

Company Announcement No. 10-2020 The Board of Directors hereby convenes the Annual General Meeting to be held on Friday 26 June 2020 at 4 pm (CET) at the offices of the company, Vigerslev Allé 77, DK-2500 Valby. To protect everyone’s safety and reduce the risk of COVID-19 spreading, we recommend that shareholders refrain from attending the general meeting in person and instead cast their votes by postal vote or proxy and attend the live webcast of the general meeting via the web site. The number of representatives from the management will be reduced to reduce the risk of infection. Agenda: The Board of Directors' report on the company’s activities in 2019.Presentation and approval of the 2019 Annual Report.Approval of the Board of Directors’ fees: a. Final approval of fees for 2019. The Board of Directors proposes unchanged approval of the fees for 2019 that were pre-approved by the general meeting in 2019. The fees are based on a base fee of DKK 450,000 (the “Base Fee”) with twice tha

Decisions of Sampo plc’s Annual General Meeting2.6.2020 14:00:00 CESTPress release

SAMPO PLC DECISIONS OF GENERAL MEETING 2 June 2020 at 3:00 pm Decisions of Sampo plc’s Annual General Meeting The Annual General Meeting of Sampo plc, held today on 2 June 2020, decided to distribute a dividend of EUR 1.50 per share for 2019. The record date for dividend payment is 4 June 2020 and the dividend will be paid on 11 June 2020. The Annual General Meeting adopted the financial accounts for 2019 and discharged the Board of Directors and the CEO from liability for the financial year. The Annual General Meeting elected eight members to the Board of Directors. The following members were re-elected to the Board: Christian Clausen, Fiona Clutterbuck, Jannica Fagerholm, Johanna Lamminen, Risto Murto, Antti Mäkinen and Björn Wahlroos. Georg Ehrnrooth was elected as a new member to the Board. The Members of the Board were elected for a term continuing until the close of the next Annual General Meeting. At its organizational meeting, the Board elected Björn Wahlroos as Chairman and Ja

Cargotec completes the ownership change of joint venture in China2.6.2020 12:00:00 CESTPress release

CARGOTEC CORPORATION, PRESS RELEASE, 2 JUNE 2020 AT 1 PM (EEST) Cargotec has completed the sale of its share of the joint venture Rainbow-Cargotec Industries Co., Ltd (RCI) in China. As part of the agreement, Cargotec acquired certain operations and assets of the joint venture from Jiangsu Rainbow Heavy Industries Co., Ltd. (RHI), and approximately 160 employees have moved over from RCI to Kalmar. On 11 May 2020, Cargotec announced plans to sell its 49% share of the joint venture to the other owner RHI. RHI now owns 100% of the former joint venture, and the new name of the company is Rainbow Industries Co. Ltd. (RIC). RIC will continue as Cargotec’s subcontractor and provide assembly services for Cargotec’s business areas Kalmar and MacGregor at the factory in Taicang, China. The change aims to simplify Cargotec’s global supply chain operations. Simplification is needed mainly because the number of complex automation projects has been growing in the past couple of years. The arrangemen

Result of Riksbank reversed auctions SEK Municipal Bonds2.6.2020 11:30:00 CESTPress release

Result of Riksbank reversed auctions SEK Municipal Bonds Results of auctions Municipal BondsAggregateAuction date6/2/2020Maturity2023Tendered volume, mln SEK750 +/- 750Volume offered, mln SEK156Volume bought, mln SEK50Number of bids3Number of accepted bids1Credit Class 1Maturity, QuarterQ1Maturity, QuarterQ2Maturity, QuarterQ3Maturity, QuarterQ4Volume Offered, mln SEK50Volume Offered, mln SEK0Volume Offered, mln SEK0Volume Offered, mln SEK0Volume bought, mln SEK50Volume bought, mln SEK0Volume bought, mln SEK0Volume bought, mln SEK0Number of bids1Number of bids0Number of bids0Number of bids0Number of accepted bids1Number of accepted bids0Number of accepted bids0Number of accepted bids0Average yield0.120 %Average yield-Average yield-Average yield-Lowest accepted yield0.120 %Lowest accepted yield-Lowest accepted yield-Lowest accepted yield-Highest yield0.120 %Highest yield-Highest yield-Highest yield-% accepted at lowest yield100.00% accepted at lowest yield-% accepted at lowest yield-% a

UPM Plywood is planning to scale down plywood production in Finland2.6.2020 11:00:00 CESTPress release

(UPM Plywood, Lahti, 02.06.2020 at 12:00) – UPM Plywood is planning to permanently close its Jyväskylä plywood mill, which is producing spruce and birch plywood. The company starts a consultation process concerning the entire personnel working at the mill. UPM Jyväskylä plywood mill employs 167 people. The Profitability of Jyväskylä plywood mill has been weak for a long time, even during periods of high-demand. Despite investments as well as savings and improvement activities, the profitability has not improved to a sustainable level. Competition in the birch plywood market is increasing constantly. New birch plywood capacity has been built especially in Russia, where the production cost level is significantly more competitive than in Finland. If realized, the planned actions would strengthen UPM Plywood’s overall competitiveness and performance in the long run. “In Finland, a full run of the capacity has not been feasible due to the terms in the woodworking industry. In addition, repe